

## REMARKS

The title has been changed to more accurately reflect the instant invention.

A paragraph entitled “ Cross-Reference to Related Applications”, and which establishes the priority claim for the instant Application has been added to the specification.

Applicant is submitting an executed “Declaration and Power of Attorney for Patent Application”.

Claims 1, 3, 5, 7-11, 13, 16-18 and 25 have been canceled and new claims 26-31 have been submitted.

Claims 21-24 have been amended to remove SEQ ID NO's unrelated to the elected invention.

Claims 4, 6 and 21-24 have been amended to clarify the language of the claims.

Claim 15 has been amended to remove reference to proteins unrelated to the elected invention.

Claims 27 and 28 are drawn to fragments from a nucleic acid sequence that hybridizes to a nucleic acid sequence encoding a flea octopamine receptor, where the fragments are 35 and 50, respectively, nucleotides in length. Support for these claims can be found, for example, in the specification on page 21, lines 1-21.

Claims 30 and 31 are drawn to fragments from a protein encoded by a nucleic acid sequence that hybridizes to a nucleic acid sequence encoding a flea octopamine receptor, where the fragments are 35 and 50, respectively, amino acids in length. Support for these claims can be found, for example, in the specification on page 20, lines 6-16. Accordingly, Applicant submits that no new matter has been entered into the Application.

### I. Declaration and Power of Attorney

Applicant notes that the originally filed “Declaration and Power of Attorney for Patent Application” (Declaration) was never executed. Therefore, Applicant submits herewith an executed Declaration. If a fee is due for this late submission, please debit Deposit Account 081930. Applicant claims small entity.

## II. Election/Restriction


The Examiner has restricted the instant claims into Groups related to (I) tick octopamine receptor proteins, nucleic acids and uses, (II) flea receptor proteins, nucleic acids and uses, (III) antibodies that bind tick octopamine receptor, and (IV) antibodies that bind flea octopamine receptor. Applicant has elected to prosecute Group II claims, which include claims 2, 4, 6, 12, 14, 15 and 19-24, and newly submitted claim s26-31. Nucleic acid molecules of Group II claims include SEQ ID NO's 1-3, 5, 6, 8-11, and 13-29. Proteins encoded by these nucleic acid molecules include SEQ ID NO's 4, 7 and 12.

## CONCLUSION

The current claims are believed to be in condition for allowance and Applicant solicits such from the Examiner. The Examiner is invited to contact the undersigned should any issues remain.

Respectfully submitted,

Dated: May 18, 2007

  
Richard J. Stern, Ph.D.  
Registration No. 50,668  
Heska Corporation  
3760 Rocky Mountain Avenue  
Loveland, Colorado 80538  
Telephone: (970) 493-7272, ext. 4174  
Facsimile: (970) 619-3011